These results suggest that FASN, PLAUR, BCL2L1, HMOX1 and RHOB may participate in the anti-Anoikis process of CTEPH, which further aggravates the condition of patients with CTEPH, which is consistent with the results of our study. This evidence concerns the gene BCL2L1 and chronic thromboembolic pulmonary hypertension.